Medpace Holdings, Inc.
Medpace Holdings is a contract research organization that runs outsourced clinical development programs for biotechnology, pharmaceutical, and medical device companies. It provides full-service Phase I-IV trial support, combining therapeutic expertise, regulatory input, and global trial operations to help sponsors move products through development faster and more efficiently.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEnd-to-end outsourced clinical trial services spanning Phase I through Phase IV.
Scientific, medical, and regulatory support embedded into trial planning and execution.
Patient enrollment, investigator recruitment, and global trial coordination services.
Products
Reported · share of revenue- Oncology29.5 %
- Metabolic29.4 %
- Other16.1 %
- Central Nervous System10.1 %
- Cardiology9.5 %
- Antiviral and Anti Infective5.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Medpace sells primarily to biotechnology, pharmaceutical, and medical device sponsors that outsource clinical development rather than run trials entirely in-house. Its core appeal is strongest for small and mid-sized biopharmaceutical companies that want a full-service CRO partner with therapeutic depth, global reach, and disciplined execution. The company also serves larger sponsors on selected programs, but customer concentration and sponsor retention remain important to the model.
They buy full-service clinical development because they often lack the internal infrastructure to run global trials efficiently.
They outsource trial design, site management, and execution to accelerate development and conserve internal capital.
They use Medpace for selected programs and therapeutic-area expertise when they need external trial capacity.
They buy regulated clinical research services for device studies and related development programs.
Strategy
Medpace is focused on expanding share in the Phase I-IV CRO market by emphasizing full-service delivery, therapeutic specialization, and disciplined execution. Management also highlights organic growth, selective bolt-on acquisitions, and continued investment in facilities, equipment, and technology to support capacity and service quality.
The company wants to capture more sponsor demand for full-service CRO outsourcing across the development lifecycle.
Therapeutic expertise is a key differentiator in winning complex studies and repeat business.
Facilities, equipment, and systems support trial execution quality and future growth.
Geography
Medpace operates globally, with approximately 6,200 employees across 46 countries as of year-end 2025 and about 6,000 employees across 44 countries at mid-2025. The business depends on international trial sites, local regulatory know-how, and access to diverse patient populations, so geographic breadth is a core part of its operating model rather than just a sales footprint.
Risks
Medpace is exposed to sponsor concentration, contract timing, and execution risk because revenue depends on winning and completing clinical trials under fixed-fee or change-order-based arrangements. It also faces industry-wide CRO risks such as patient enrollment challenges, pricing pressure, regulatory disruption, cybersecurity, and global operating complexity.
- Sponsor contract loss or non-renewalImpact: HighLikelihood: Medium
Revenue depends on ongoing clinical programs, so cancellations or delays can quickly reduce utilization and backlog conversion.
Exposure: Biopharma and device sponsor relationships
- Fixed-fee pricing and change-order executionImpact: HighLikelihood: Medium
If study costs exceed estimates or change orders are delayed, margins can fall because the company bears execution risk.
Exposure: Clinical trial contracts
- Patient recruitment and investigator availabilityImpact: HighLikelihood: Medium
Trials depend on enrolling patients and securing investigators, and delays can push out revenue recognition and increase costs.
Exposure: Global clinical operations
- Cybersecurity and information system outagesImpact: HighLikelihood: Medium
Clinical operations rely on systems such as ClinTrak and sensitive sponsor data, so breaches or outages can disrupt delivery and damage reputation.
Exposure: Operational systems and confidential trial data
- Customer and therapeutic concentrationImpact: MediumLikelihood: Medium
A limited number of large sponsors or therapeutic classes can create outsized exposure to program cancellations or class-wide setbacks.
Exposure: Top ten customers and concentrated therapeutic areas
- International and geopolitical exposureImpact: MediumLikelihood: Medium
A broad country footprint creates exposure to local regulation, political instability, FX movements, and cross-border operating complexity.
Exposure: 46-country operating platform
Accounting
Judgemental itemsClinical trial revenue depends on estimating progress and handling change orders, which can shift timing and margins.
Impact: Affects quarterly revenue, gross margin, and backlog conversion
Management’s estimates of future conversion and cost-to-complete influence reported performance and visibility.
Impact: Affects revenue outlook and margin comparability
The company recorded liabilities for uncertain tax positions that depend on judgment across domestic and foreign jurisdictions.
Impact: Can create future tax expense, interest, and penalties
Management does not currently provide taxes on foreign earnings, which affects deferred tax accounting and liquidity assumptions.
Impact: Affects tax expense and potential repatriation costs
Facility and infrastructure commitments support growth but also create fixed obligations that affect cash planning.
Impact: Affects liquidity disclosure and future cash requirements
Similar listed companies
Publicly listed companies with a comparable business focus.
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
NextCure, Inc.
NXTC · Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
Medline Inc.
MDLN · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026